CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

NCT ID: NCT05613348

Last Updated: 2024-03-18

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-01
• Study Completion Date: 2028-12-01

Brief Summary

This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

Detailed Description

CD19 CAR-T cells treating B-cell hematological malignancies have achieved unprecedented success. In this study, we investigated new third-generation autologous T cells (CAR19T2 T cells) genetically modified with humanized anti-CD19 construct incorporating CD28 and Toll-like receptor 2 (TLR2) costimulatory domains. CAR19T2 T cells will be modified before the infusion to those which could identify and kill the tumor cells (CD19+ cells). This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor T cell (CAR19T2 T Cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.

Conditions

B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma, Unspecified

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

humanized CAR19T2 T cell to B-cell acute lymphoblastic leukemia/lymphoma

Patients received fludarabine and cyclophosphamide (Flu/Cy) for lymphodepletion (Cy at 300-500 mg/m2/dose for four days and Flu at 20-30 mg/m2/dose for two days) before CAR19T2 T cells administration. This CAR19T2 T cell will be infused over 30 minutes on days Day 0.

Group Type: EXPERIMENTAL

CD19 CAR T-Cell(CAT19T2)

Intervention Type: BIOLOGICAL

Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously

Interventions

CD19 CAR T-Cell(CAT19T2)

Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. ≥1 year old and ≤18 years.

2. Patients with relapsed and/or refractory CD19-positive B-cell acute leukemia/lymphoma.

3. Leukemia/lymphoma relapsed after allogeneic hematopoietic stem cell transplantation within four weeks, all immunosuppressive agents were stopped for at least four weeks, and no active graft-versus-host disease(GVHD) was detonated.

4. Lansky play (≤16 years old) scale ≥60% or Karnofsky (>16 years old) score ≥60% and Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory to assess the performance score.

5. Adequate vascular access leukapheresis procedure. Absolute Lymphocyte count (ALC) greater than or equal to 100 cells/μL.

6. Adequate renal, hepatic, pulmonary, and cardiac function is defined as the following:

• Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 5 upper limit of normal (ULN), Total bilirubin ≤2 x ULN.
• A serum creatinine based on age/gender as follows: 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female);2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female); 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female); 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female); 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female); >=16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female).
• Baseline oxygen saturation > 92% on room air.
• Echocardiogram or left ventricular ejection fraction (LVEF) greater than or equal to 45% confirmed by echocardiogram, no evidence of pericardial effusion (except trace or physiological), and no clinically significant arrhythmias.

7. Life expectancy of greater than or equal to 3 months.

8. Patients or legal guardians must sign an informed consent.

Exclusion Criteria

1. Prior received any other CAR T cell and tumor vaccine treatment.

2. Patient with a previous history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.

3. Patient with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.

4. Acute GVHD grade II-IV (Glucksberg criteria) or chronic GVHD requiring systemic treatment within 4 weeks before enrollment.

5. History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, etc. (Except for CNS involvement of underlying hematological malignancy)

6. Severe psychological disorder or psychiatric illness.

7. Combined with life-threatening severe organ failure.

8. Major non-medicinal surgery within four weeks.

9. Received other clinical trials within four weeks. 10. Women who are pregnant or breastfeeding.

11. The following drugs patients must be stopped prior to leukapheresis:

• Tyrosine Kinase Inhibitor (TKI) must be discontinued more than or equal to 3 days before collection.
• Salvage chemotherapy must be stopped > 2 weeks and intrathecal chemotherapy in the 7 days prior to collection.
• Systemic steroid therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone in the 7 days before collection.
• Donor lymphocyte infusions (DLI) and Immunosuppressive therapies within 4 weeks before collection.
• Received clofarabine or cladribine within 3 months prior to collection.
• Receive blinatumomab within 4 weeks, inotuzumab ozogamicin, and rituximab within 4 months, and alemtuzumab within 6 months before collection.

12. Tyrosine Kinase Inhibitor within 1 week and asparaginase within 4 weeks prior to CAR T-cell infusion.

13. In the opinion of the PI, patients are present for any condition, not for enrollment.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Guangdong Zhaotai Cell Bio-tech Co., LTD

UNKNOWN

Sponsor Role: collaborator

Zhujiang Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lihua Yang

Role: PRINCIPAL_INVESTIGATOR

Zhujiang Hospital

Locations

Guangdong Zhaotai Cell Bio-tech Co., LTD

Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University

Guanzhou, Guangdong, China

Countries

China

Other Identifiers

2022-KY-094

Identifier Type: -

Identifier Source: org_study_id